Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?

Kristina Busygina, Viola Denzinger, Isabell Bernlochner, Christian Weber, Reinhard Lorenz, Wolfgang Siess*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1212-1221
Number of pages10
JournalThrombosis and Haemostasis
Volume119
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • ACALABRUTINIB ACP-196
  • BRUTONS TYROSINE KINASE
  • Btk inhibitor
  • CA2+ ENTRY
  • COMPLEMENTARY ROLES
  • GLYCOPROTEIN-VI
  • GPIb
  • GPVI
  • GPVI-FC
  • PLATELET THROMBUS FORMATION
  • SRC FAMILY
  • TERM-FOLLOW-UP
  • X-LINKED AGAMMAGLOBULINEMIA
  • X-linked agammaglobulinemia
  • bleeding
  • platelet
  • IBRUTINIB TREATMENT

Cite this

Busygina, K., Denzinger, V., Bernlochner, I., Weber, C., Lorenz, R., & Siess, W. (2019). Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs? Thrombosis and Haemostasis, 119(8), 1212-1221. https://doi.org/10.1055/s-0039-1687877